Drug Metabolism and Disposition 2014-12-01

In vitro metabolism and drug-drug interaction potential of UTL-5g, a novel chemo- and radioprotective agent.

Jianmei Wu, Jiajiu Shaw, Sarah Dubaisi, Frederick Valeriote, Jing Li

文献索引：Drug Metab. Dispos. 42(12) , 2058-67, (2014)

全文：HTML全文

摘要

N-(2,4-dichlorophenyl)-5-methyl-1,2-oxazole-3-carboxamide (UTL-5g), a potential chemo- and radioprotective agent, acts as a prodrug requiring bioactivation to the active metabolite 5-methylisoxazole-3-carboxylic acid (ISOX). UTL-5g hydrolysis to ISOX and 2,4-dichloroaniline (DCA) has been identified in porcine and rabbit liver esterases. The purpose of this study was to provide insights on the metabolism and drug interaction potential of UTL-5g in humans. The kinetics of UTL-5g hydrolysis was determined in human liver microsomes (HLM) and recombinant human carboxylesterases (hCE1b and hCE2). The potential of UTL-5g and its metabolites for competitive inhibition and time-dependent inhibition of microsomal cytochrome P450 (P450) was examined in HLM. UTL-5g hydrolysis to ISOX and DCA in HLM were NADPH-independent, with a maximum rate of reaction (Vmax) of 11.1 nmol/min per mg and substrate affinity (Km) of 41.6 µM. Both hCE1b and hCE2 effectively catalyzed UTL-5g hydrolysis, but hCE2 exhibited ∼30-fold higher catalytic efficiency (Vmax/Km) than hCE1b. UTL-5g and DCA competitively inhibited microsomal CYP1A2, CYP2B6, and CYP2C19 (IC50 values <50 µM), and exhibited time-dependent inhibition of microsomal CYP1A2 with the inactivation efficiency (kinact/KI) of 0.68 and 0.51 minute(-1)·mM(-1), respectively. ISOX did not inhibit or inactivate any tested microsomal P450. In conclusion, hCE1b and hCE2 play a key role in the bioactivation of UTL-5g. Factors influencing carboxylesterase activities may have a significant impact on the pharmacological and therapeutic effects of UTL-5g. UTL-5g has the potential to inhibit P450-mediated metabolism through competitive inhibition or time-dependent inhibition. Caution is particularly needed for potential drug interactions involving competitive inhibition or time-dependent inhibition of CYP1A2 in the future clinical development of UTL-5g.Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.

相关化合物

  • 右羟吗喃
  • 酮康唑
  • 磺胺苯吡唑
  • 对乙酰氨基苯酚
  • 罗格列酮
  • 奎尼丁
  • 二水槲皮素
  • 呋拉茶碱
  • 醋氨酚-D4
  • 槲皮素

相关文献：

Morphological behaviour and metabolic capacity of cryopreserved human primary hepatocytes cultivated in a perfused multiwell device.

2015-01-01

[Xenobiotica 45(1) , 29-44, (2014)]

Evaluation of thein vitro/in vivodrug interaction potential of BST204, a purified dry extract of ginseng, and its four bioactive ginsenosides through cytochrome P450 inhibition/induction and UDP-glucuronosyltransferase inhibition

2014-06-01

[Food Chem. Toxicol. 68 , 117-27, (2014)]

Determination of sitafloxacin in human plasma by liquid chromatography–tandem mass spectrometry method: Application to a pharmacokinetic study

2014-04-15

[J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 957 , 36-40, (2014)]

Phenotyping of CYP450 in human liver microsomes using the cocktail approach.

2014-08-01

[Anal. Bioanal. Chem 406(20) , 4875-87, (2014)]

Development and validation of a liquid-chromatography high-resolution tandem mass spectrometry approach for quantification of nine cytochrome P450 (CYP) model substrate metabolites in an in vitro CYP inhibition cocktail.

1999-09-24

[Anal. Bioanal. Chem 406(18) , 4453-64, (2014)]

更多文献...